Nuvation Bio
Nuvation Bio Inc is an American multinational clinical-stage biopharmaceutical enterprise specializing in the discovery, research, development, and commercialization of revolutionary therapeutic candidates and targeted small-molecule inhibitors designed to treat difficult oncological cancers with high unmet medical needs across the United States and international medical markets. Operating advanced R&D laboratories and clinical development centers, the company pioneers precision oncology treatments. Its core business operations encompass oncology drug discovery, preclinical therapeutic design, clinical trials management, and biopharmaceutical R&D partnerships. Revenue is derived primarily from research grants, collaborative development agreements, and capital financing arrangements, pending commercial drug approval. Nuvation Bio holds an established market position in clinical-stage precision oncology therapeutics. The company is headquartered in New York City, New York, United States, and its common stock trades on the New York Stock Exchange under the ticker NUVB.
4 of the funds FundTelligence covers report a position in Nuvation Bio.
- Legal name
- Nuvation Bio Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Nuvation Bio
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)